Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 12, 2019 at 01:58 pm EST
Share
Yung Zip Chemical Ind. Co., Ltd. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was TWD 99.702 million compared to TWD 92.847 million a year ago. Operating loss was TWD 3.707 million compared to TWD 6.210 million a year ago. Net income was TWD 5.684 million compared to net loss of TWD 3.746 million a year ago. Basic earnings per share was TWD 0.13 compared to basic loss per share of TWD 0.09 a year ago. For the nine months, sales was TWD 313.991 million compared to TWD 242.239 million a year ago. Operating income was TWD 13.645 million compared to operating loss of TWD 21.259 million a year ago. Net income was TWD 24.708 million compared to net loss of TWD 15.806 million a year ago. Basic earnings per share was TWD 0.58 compared to basic loss per share of TWD 0.37 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
